Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · The Lancet · 2019 · 871 citations

Medicine, Radiation Oncology, Urology +16

Pelvic Normal Tissue Contouring Guidelines for Radiation Therapy: A Radiation Therapy Oncology Group Consensus Panel Atlas

Hiram A. Gay, H. Joseph Barthold, Elizabeth O’Meara et al. · International Journal of Radiation Oncology*Biology*Physics · 2012 · 537 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Sample size tables for exact single‐stage phase II designs

Roger A’Hern · Statistics in Medicine · 2001 · 398 citations

Public Health, Biostatistics, A/b Testing +16

How low is the α/β ratio for prostate cancer?

Jian Z. Wang, Mariana Guerrero, X.Allen Li · International Journal of Radiation Oncology*Biology*Physics · 2002 · 334 citations

Medicine, Oncology, Urology +9